All In Biotech

Drug Trial Radar · NCT07569757

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

A Randomized, Open-Label, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2934 Injection Versus Investigator-Selected Regimens in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Dec 2028

Study completion Dec 2030

Sponsor

Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The primary objective of the study is to demonstrate the efficacy of TQB2934 for injection compared to the investigator-selected regimen in subjects with relapsed or refractory multiple myeloma (RRMM) by evaluating progression-free survival (PFS).

Conditions

  • Multiple Myeloma

Interventions

  • TQB2934 injectionDrug

    TQB2934 injection is a bispecific antibody targeting B-cell maturation antigen (BCMA) and Cluster of Differentiation 3 (CD3).

  • Pomalidomide CapsuleDrug

    Pomalidomide capsules are an immunomodulatory(IMiD).

  • Selinexor tabletsDrug

    Selinexor is a selective nuclear export protein inhibitor.

  • Dexamethasone tabletsDrug

    Dexamethasone tablets are a type of adrenocortical hormone drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Baseline up to 5 years

Locations

49 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Chao-Yang Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Jishuitan Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Southwest Hospital of Amu

    Chongqing, Chongqing Municipality, China

  • Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Central Hospital)

    Lanzhou, Gansu, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Cangzhou People'S Hospital

    Cangzhou, Hebei, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China

  • The Second Hospital of Hebeimedical University

    Shijiazhuang, Hebei, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Luoyang Central Hospital

    Luoyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Henan Provincial People'S Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital Of Zhengzhou University

    Zhengzhou, Henan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital Of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi'an, Shaanxi, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University(Shandong Provincial Hospital)

    Jinan, Shandong, China

  • Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)

    Jinan, Shandong, China

  • Jining No.1 People'S Hospital

    Jining, Shandong, China

  • Qingdao Municipal Hospital

    Qingdao, Shandong, China

  • ZhongShan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.